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Due to the complex nature of cancer, a variety of strategies are being
employed to treat patients. Among these are oncolytic viruses that conditionally
replicate in tumor cells with specific cellular landscapes. Several viruses including
Herpesviruses, Adenoviruses, and Poxviruses, predominantly vaccinia virus (VV),
have been explored for their oncolytic potential. Most of these viruses can
productively infect a variety of cell types and it is one goal to create conditionally
lethal viruses that can only replicate in tumor cells. Due to the prevalence of p53
inactivating mutations in cancers viruses that are restricted to p53 null cells are
desirable and have been developed. We were interested if we could develop a similar
mutant in the tanapox virus. Here we describe the identification of a protein from the
142R open reading frame of the tanapox virus genome that is orthologous to the B1R
protein from VV which is known to down regulate p53 by phosphorylation. We
determine that like B1R, TPV142R encodes a serine threonine kinase that can
phosphorylate the tumor suppressor p53. However, we were not able to isolate a
TPV142R knockout virus using our current system of viral mutant generation
indicating that the p142R protein is essential for viral replication.

This was

confirmed by using shRNA to target the knockdown of 142R which resulted in a

decrease in viral replication.

Due to the apparent necessary function that 142R

protein provides, TPV lacking 142R may not make a suitable oncolytic virus.
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INTRODUCTION

Poxviruses

Poxviridae is a large family of DNA viruses that infect vertebrates and
invertebrates (Moss, 1996). Members of the family of poxviruses are characterized as
viruses that replicate in the cytoplasm of their host and are able to synthesize mRNA
via the enzymes contained in the virion. These enzymes are encoded in the viral
genome, which is single, linear, and dsDNA with hairpin loops at each end. These
hairpins at the ends of their genomes are A + T rich, not completely base-paired and
are inverted or complementary in sequence. The region directly adjacent to the hairpin
loops is highly conserved amongst poxviruses (DeLange et al., 1986). At both ends
of the genome are inverted terminal repeats (ITRs) that are identical to one another
but oppositely oriented (Moss, 1996). These regions are highly variable and may
include coding regions which puts some genes at both ends of the genome (Figure 1).

Figure 1. Inverted Terminal Repeats and Hairpin Loops of Tanapox Virus.
The family is further divided into subfamilies Chordopoxvirinae (vertebrate)
and Entomopoxvirinae (insects) by host specification (Moss, 1996). Among
chordopoxviruses there are eight genera based on genetic and antigenic relatedness,
1
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similar morphology and a similar host range. Within each genus, serologic crossreactivity for group-specific NP antigen has been demonstrated. With complete
sequences being reported for each genera of Chordopoxvirinae and two
Entomopoxvirinae, it has been noted that nearly 100 genes are conserved amongst
Chordopoxvirinae and 50 genes amongst all poxviruses (Moss, 2007). These genes
are largely nonoverlapping and point to the nearer end of the genome. More
conserved genes are more centrally located and are essential for replication, while
genes involved in host interactions, which are highly variable, are located more
peripherally in the genomes.
Viral Particles
Poxviruses are larger than other animal viruses to the extent that they are
visible by light microscopy (Moss, 1996). By reconstructed images of cryoprepared
electrol tomography they appear to have a barrel shape measuring about 360 by 270
by 250 nm (Cyrklaff et al., 2005, Dubochet et al., 1994). There is a 30 nm membrane
surface layer that surrounds a homogenous core that is studded with 20 nm spikes
(Moss, 1996). The core has a dumbbell shape made up of an outer and inner layer
with lateral bodies attached within the concavities (Figure 2). Within the core are
four insoluble structural proteins that account for 70% of the weight of the core
(Paoletti & Moss, 1974). Infectious particles contain all the enzymes and factors they
need to synthesize polyadenylated, capped and methylated mRNAs (Wei & Moss,
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1975). This includes early transcription factor which can begin the chain reaction of
virus production (Moss, 1996).

Figure 2. Schematic of a Poxvirus.
Entry and Early Transcription
Although not completely clear, mature virions (MV) are thought to fuse with
the cell membrane, possibly with the help of a cellular receptor, in order to enter the
cell (Chang & Metz, 1976, Twardzik et al., 1985). However, viral envelopes need a
low pH environment to allow productive entry (Townsley et al., 2006), and more
recently vaccinia virus has been shown to enter through apoptotic mimicry (Mercer &
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Helenius, 2008). Extracellular enveloped virions (EEV) require the removal of the
outer membrane prior to fusion (Moss, 2007). This disruption can occur with a
neutral pH or potentially within endosomes (Ichihashi, 1996, Vanderplasschen et al.,
1998). Once the virus is attached there is a signaling cascade that causes membrane
rearrangements and actin formation (Locker et al., 2000). MV then enter the cell via a
complex of 11-12 transmembrane proteins that are conserved in all poxviruses (Moss,
2012). Viral cores are then transported to sites of transcription via microtubules and
mRNA synthesis begins (Moss, 2007). Early transcription requires both RNA
polymerase and early transcription factor which are both packaged in the virion and
do not need to be transcribed (Moss, 1996). The genes transcribed at this point of
infection contain promoter sequences that are conserved between members with the
same genera, which may explain how they can rescue one another after heatinactivation. The mRNA from early genes can be detected as early as twenty minutes
postinfection and peak at two hours (Baldick & Moss, 1993). These genes encode
proteins involved in viral DNA replication, intermediate gene expression and host
interactions (Moss, 1996). Serine/threonine protein kinases have been found to have
early expression in addition to presence in the virions to aid in DNA replication
(Kleiman & Moss, 1975). Early gene expression ends with the disruption of the virus
core, called uncoating, via the nucleoprotein complex passing through breaches in the
core wall (Moss, 2007). See figure 3 for an overview of poxvirus replication.
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Figure 3. Hypothetical Tanapox Virus Life Cycle (Essani et al., 2011).
DNA Replication
DNA replication occurs in foci of replication sites in the cytoplasm termed
factory areas, using viral counterparts of cellular replication proteins (Moss, 1996). In
order to replicate DNA, deoxyribonucleotides need to be synthesized due to
suboptimal precursor pools. This is accomplished through the viral enzymes
thymidine kinase, thymidylate kinase, ribonucleotide reductase and dUTPase. The
time it takes for DNA replication spans from one to sixteen hours depending on the
poxvirus family member. It has been speculated that replication begins at both ends
following terminal nicks and does not require an origin site. The proteins necessary
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for replication are DNA polymerase, an ATP/GTP binding motif protein, a
serine/threonine kinase packaged into virions, a protein that encodes uracil DNA
glycosylates and an ATP-dependent DNA ligase. In addition, concatemer
intermediates need to form and resolve into unit-length molecules. Concatemer
junctions appear at the ends of the genome as copies of the hairpin loop. There is a
strong connection between replication and recombination which indicates that
poxviruses cannot biochemically distinguish between the two processes (Fisher et al.,
1991). High rates of recombination occur within poxvirus-infected cells allowing
viral genomes to rapidly eliminate direct repeats and often result in single and double
crossover products (Ball, 1987).
Intermediate Transcription
Intermediate-stage genes are expressed after DNA replication but before the
expression of late genes. Some early genes are required for intermediate gene
transcription, just as some intermediate genes transactivate late gene expression.
Intermediate-stage promoters contain two important regions: a 14-bp-core element
that is 10-11 bp upstream of the critical 4-bp initiator element where initiation takes
place (Baldick et al., 1992). Intermediate-stage transcription requires RNA
polymerase, virus-encoded capping enzyme and intermediate transcription factor in
order for production of RNA (Rosales et al., 1994, Vos et al., 1991).
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Late Transcription
Late transcription follows intermediate gene expression and genes in this
category are clustered in the central region of the genome (Moss, 1996). Major virion
components and necessary factors for early gene production are transcribed during the
late stage. Late stage mRNAs have 5’ caps, are of a heterogeneous length and are
polyadenylated due to RNA polymerase slippage. However, they lack a defined 3’
end (Mahr & Roberts, 1984).
Viral Packaging
Soon after late transcription, intracellular immature virions (IV) are assembled
in circumscribed, granular, electron dense areas of the cytoplasm (Moss, 2007). IVs
begin in a crescent shape with a membrane containing a brushlike border of spicules
on the convex surface and granular material on the concave side. Subsequently, IVs
become circular with a dense nucleoprotein mass, which enters envelope before it is
completely sealed and is embedded in the granular matrix. Major structural proteins
are then processed and the IV becomes enveloped. Some poxvirus IVs then become
occluded in a dense protein matrix of the cytoplasm or at sites of virus replication and
assembly which help protect them from the environment. Then the IV becomes more
barrel-shaped rather than spherical and is now considered to be mature.
This now mature virus then moves to the cell periphery where it becomes
membrane wrapped by the Golgi or early endosomal network and is now considered a
wrapped virion (WV). After being wrapped the virus is transported to the plasma
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membrane on actin-containing microfilaments (Stokes, 1976) where the virus fuses
and is externalized to become EEV (Moss, 1996), containing an additional lipoprotein
envelope (Payne, 1978). At this time the EEV can adhere to the cell surface or are
released (Moss, 1996). Adherent EEVs go on to mediate cell-to-cell spread, while
released EEVs provide long-range dissemination (Blasco & Moss, 1992).
Viral Infection
Once the virus infects the cell, multiple events occur aside from DNA
transcription and replication. Infection results in cytopathic effects (Bablanian et al.,
1978), changes to membrane permeability, and inhibition of host DNA, RNA and
protein synthesis (Moss, 1996). Upon infection, many poxviruses induce hyperplastic
responses and sometimes tumor formation due to the secretion of growth factors
related to both epidermal growth factor (EGF) and transforming growth factor α
(Blomquist et al., 1984). These growth factors help contribute to virulence in vivo
(Moss, 1996). In defense to poxvirus infection, the host mounts a nonspecific
immune response involving interferons, complements, natural killer cells, cytotoxic T
cells and antibodies (Buller & Palumbo, 1991). However, poxviruses counter and
evade the immune response by several different mechanisms: including a lack of a
latent phase (Moss, 1996). Poxviruses have also evolved multiple proteins that
interfere with principal cytokines including interferons, interleukins and tumor
necrosis factors involved in host defense. In addition, poxviruses contain short
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consensus repeats to inhibit complement activation pathways to allow for maximal
infection.
Yatapox
Yatapox is a genus of the subfamily Chordopoxvirinae that contains two
viruses: yaba-monkey tumor virus (YMTV) and tanapox virus (TPV) (Nazarian et al.,
2007a). Tanapox virus is considered to have two strains, the central virus called
tanapox virus from equatorial Africa and the other called yaba-like disease virus
(YLDV) from U.S. primate facilities (Downie & España, 1973). Both tanapox virus
and YMTV have a narrow host range of primates, both human and nonhuman, and are
the smallest of the chordopoxviruses (Brunetti et al., 2003). YMTV has been
sequenced and has open reading frames that are highly conserved with TPV, despite
their vast clinical differences. YMTV induces substantial tumor formation that is
derived from histiocytes that migrate to the site of infection. Once the histiocyte
forms a polyclonal tumor (though never becomes invasive), the tumor will regress
when mononucleated cells move into the lesion until it is cleared and the infection is
gone (Damon, 2007).
Tanapox Virus
Tanapox virus was first publicized when outbreaks occurred along the Tana
River in Kenya in 1957 and 1962 (Downie et al., 1971). These were both years in
which there was prolonged, extensive flooding along the river that left local tribes
isolated on islands of high ground with not only their livestock, but wild animals as
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well. In 1957, it was the children of the mission school in the swamp forest flood
plain village of Ngau that were infected leading to speculation that it targeted
children. However, in 1962 the riverine Wapakono tribe along the middle reaches of
the Tana River between Garissa and Garsen were infected. In this case several
hundred people were infected of both sexes and all ages, making it clear that tanapox
virus is not limited to children. Due to the fact that these outbreaks were limited;
despite the tribe and the children being in contact with others, implicates mosquitoes
as the most likely vector candidate. The flooding in these years made ideal breeding
grounds for the Mansonia mosquitoes that were able to feast on the stranded people at
a rate of about seven hundred bites per hour in the evenings. When comparing
tanapox virus with other mosquito-transmitted viruses, it was found that West Nile
virus infection is quite similar (Manson-Bahr & Downie, 1973). The antibody
distribution for both viruses is similar as well as the age, sex and tribe specific
incidence. This adds further evidence for mosquitoes being the responsible vector of
transmission.
In addition there has never been a reported case of human-to-human
contraction of the disease. However, there is evidence of primate to human
transmission of the disease, as in the outbreak in U.S. primate facilities in 1966
(Downie & España, 1973). The U.S. virus was eventually named yaba-like disease
virus (YLDV) and is phenotypically identical to tanapox virus. However, the slight
differences in their restriction digest patterns suggested YLDV and tanapox virus may
be different strains of the same virus (Knight et al., 1989), which was later confirmed
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when these viruses were sequenced (Lee et al., 2001, Nazarian et al., 2007a). For
both of these strains it is believed that some species of primate is the reservoir due to
the fact that only primates are susceptible and there are several species of primates
living along the Tana River, although this has never been confirmed (Downie &
España, 1973).
Endemic Virus
After these three outbreaks, it was noted that tanapox virus is actually endemic
to all of equatorial Africa (Knight et al., 1989). Neutralizing and complement-fixing
antibodies have been found in a wide variety of people in the area well after the
outbreaks indicating their infection had been in the last two years of sampling
(Manson-Bahr & Downie, 1973). Infected persons have also been found outside the
Tana River Valley, as in human primates in Zaire in 1977 and 1981 and vervet
monkeys in Ethiopia. Samples were taken from many of these areas and further
examined for understanding of their relationship to other poxviruses.
Viral Infection
Morphologically tanapox virus resembles other poxviruses, with its dumbbellshaped core encased in an outer membrane making an overall brick-shaped
appearance (Nazarian et al., 2007a). However, tanapox virus often has an extra
envelope which is rarely found in samples from orthopox virus infections (Fenner,
1996). In cell culture tanapox virus forms focal lesions that have intense granularity
leading to the cells rounding up. In primates the infection symptoms manifest after an
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unknown number of days in a short febrile illness (Downie et al., 1971). A lesion
develops during this time that begins as a small nodule that becomes papular and
increases in size until the end of week two where it can be up to fifteen millimeters in
diameter (Fenner, 1996). The area around the nodule becomes an edematous zone
and a large erythematous areola. The nodule then generally ulcerates and gradually
heals for a few weeks, leaving behind a scar. Despite the fact that this infection can
be contracted anywhere in equatorial Africa, depending in what country this occurs in
can determine the number of lesions as well as the location on the body. In Kenya the
lesions are usually above the waistline and singular (Downie et al., 1971), however in
Zaire they are more prevalent on the lower limbs with multiple lesions occurring
(Fenner, 1996).
Diagnosis
When diagnosing a patient with tanapox virus it is often difficult to
differentiate from other poxviruses. Immediate, visual tests to distinguish tanapox
virus from smallpox virus can be done. These are based on the fact that tanapox virus
lesions are larger, firm, solid, have slower evolution while exhibiting no postulation
(Downie et al., 1971). Further testing can be done on samples from patients to
confirm the presence of an enveloped virion in the electron microscopy, the lack of
growth on choriallantois of chick embryos, and PCR determination with tanapox virus
primers (Dhar et al., 2004). Once diagnosis has been made no treatment need be
administered due to its ability to heal on its own without patient risk.
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Tropism
The tropism of tanapox is rather narrow, which may explain the location of
lesions on the body as well as the behavior of tanapox virus. Tanapox virus is a selflimiting infection which may be due to its optimal temperature of 34oC being below
host core body temperature (Nazarian et al., 2007b). Tanapox virus uses monocytes
for replication due to their rapid division and movement to sites of naturally occurring
infections which may be the cause of the acute febrile illness. Tanapox virus cannot
replicate in a cell in which the cell cycle is arrested, limiting its ability of infecting the
body to that of proliferating cells.
Viral Genome
With both known strains of tanapox virus sequenced, many of the putative
functions of the predicted 151 open reading frames have been hypothesized (Lee et
al., 2001, Nazarian et al., 2007a). These sequences have been compared to both other
poxviruses and tanapox virus isolates from different decades to determine homology,
evolution and function of these genes. The tanapox virus genome is predicted to
encode for all the necessary proteins for viral DNA replication and packaging. In
addition, it also encodes for proteins involved in evading the immune response in
humans, some of which have been examined in detail. Tanapox virus produces an
interleukin-10 related cytokine (Bartlett et al., 2004), an inhibitor of interleukin-18
(Nazarian et al., 2008), an inhibitor of tumor necrosis factor (Brunetti et al., 2003),
multiple anti-cytokines (Essani et al., 1994), and glycoproteins to inhibit interferons
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(Huang et al., 2007). Furthermore, tanapox virus expresses a member of the
complement control protein family (Law et al., 2004) and a chemokine receptor
(Najarro et al., 2006).
Poxviruses with Oncolytic Potential
Vaccinia virus has been included in the many viruses that have been used to
target cancer cells. Ever since the early 20th century, viruses have been considered
promising ways of targeting and destroying cancer cells (Sinkovics & Horvath, 2000).
Since that time, many viruses have been tested in both experimental settings and in
humans, with most ending in failure or with side effects too harmful to warrant
continuation (Vähä-Koskela et al., 2007). However, resurgence in the 1990s, with
new biotechnology methods available and the beginnings of gene therapy, made
virotherapy an available option for cancer treatment plans. Virotherapy can be
accomplished in a variety of ways that can be either direct or indirect.
Indirect Virotherapy
Indirect methods are when the viruses induce an immune response from the
host to target tumor cells. The foremost way of evoking the desired response is
through tumor vaccination or cancer immunotherapy (Vähä-Koskela et al., 2007). In
this way the body can maintain immunologic memory as well as evoke tumor-specific
immunity to eradicate established tumors (Schuster et al., 2006). What’s more is that
even simple vaccination against common pathogens has indirect effect of crossprotection between viral epitopes and cancer (Kölmel et al., 2005). Viruses can also
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be used as adjuvants that enhance tumor cell recognition by T cells or dendritic cells
when they encode immunostimulatory cytokines (Vähä-Koskela et al., 2007).
However, viral transduction into the tumor vasculature remains an ideal target as a
way to prevent angiogenesis and oncotoxic prodrug production.
Direct Virotherapy
In order to target tumor cells, viruses must be able to select between normal
cells and cancer cells, which can be achieved either naturally or through viral
engineering. For a virus, being able to distinguish between these two cell types may
determine its success in propagation. Cancer cells provide the virus with a fertile
ground for replication due to the loss of intracellular defense mechanism components
(Cahill et al., 1999). These cells are often easier for the viruses to infect because
some malignant cells express higher levels of viral receptors than normal cells
(Shafren et al., 2004). Viral tropism towards cancer can be enhanced by engineering
the virus to be conditionally replicating (Vähä-Koskela et al., 2007), by taking
advantage of the fact that many cancer cells have activated genetic pathways or loss of
tumor suppressors (Kim et al., 2006). Adenovirus ONYX-015 is an example in
which the E1B gene has been deleted, restricting its replication to cells not containing
a wild-type p53, as is the case in many cancers. Viruses have also been engineered to
express exogenous cytotoxic genes or modified to prevent harmful side effects due to
viral infection. Other viruses inherently act by not killing the cell, but rather by
preventing cellular transformation and tumorigenesis, as seen in parvoviral infection
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of tumors (Iseki et al., 2005). These viruses cause oncosuppression through histone
acetylation by their nonstructural proteins.
Clinical Success
Among the variety of oncolytic viruses there are three generations. The first
generation are the viruses that have inherent capacity for tumor cells such as reovirus
and vesicular stomatitis virus (Kirn & Thorne, 2009). Then there are the second
generation viruses consisting of deletion mutants that are engineered for cancer
specificity such as adenovirus and herpes simplex virus. For both of these categories
clinical trials have deemed them safe and selective, but lacking in potency (Liu et al.,
2008). This is why in third generation oncolytic viruses the added strategy of arming
the viruses has shown more success, such as in vaccinia virus (Kim et al., 2006).
Poxviruses as Cancer Therapeutic Agents
Many viruses have been used to target cancer cells, with one of them being
vaccinia virus. Several approaches have been used to adapt vaccinia virus for use as
an anti-cancer agent. They are modified viruses that have been used to deliver tumorassociated antigens (Conry et al., 2000), cytokines (Mastrangelo et al., 1999) and
costimulatory molecules (Hodge et al., 1999) to induce an antitumor immune
response. Vaccinia virus has also been used to deliver genes for enzyme-prodrug
therapy (Gnant et al., 1999b) and sensitization to systemic treatment with tumor
necrosis factor (Gnant et al., 1999a). However, vaccinia virus has some drawbacks in
that it infects both tumor and non-tumor cells (Guo et al., 2005), and hosts often have
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a pre-existing immunity to it (Hu et al., 2001) sometimes making it a problematic
system. For this reason, other poxviruses, such as YLDV, are now being examined
for oncolytic potential. YLDV shows potential because it does not cross-react with
vaccinia virus antibodies, replicates in human cells, and has relatively mild infection
under normal conditions making it safer to work with (Paulose et al., 1998). For all
of these reasons, YLDV and tanapox virus may be the future in fighting cancer
through virotherapy.
p53
p53 is a classical tumor suppressor gene that is mutated in over half of all
human tumors (Ryan et al., 2001). Under normal conditions p53 is kept at a low
steady state level that dramatically increases under cellular stress conditions (ElDeiry, 1998). These stresses include DNA damage, telomere attrition, oncogene
activation, hypoxia, and loss of normal growth and survival signals (Ryan et al.,
2001). Once p53 becomes activated, many possible responses could occur which
include differentiation, senescence, DNA repair, inhibition of angiogenesis, cell cycle
arrest or apoptosis (Bates & Vousden, 1999) (See figure 4).
Downstream Transcription
The response depends on what p53 targets for transcriptional upregulation.
Upregulation of the cyclin dependent kinase inhibitor p21 induces a cell cycle arrest
response (El-Deiry, 1998). This upregulation is essential to sustain cell cycle arrest in
G2 after DNA damage occurs (Bunz et al., 1998). Ribonucleotide reductase (p53R2)
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can then be induced for DNA repair (Tanaka et al., 2000). If repair is not possible
then p53 can stimulate apoptosis by inducing mitochondrial localized proteins Bax,
NOXA (Oda et al., 2000a), PUMA (Yu et al., 2001) and p53AIP1 (Oda et al., 2000b)
that trigger cytochrome c release. p53 can also trigger death receptor transcription
such as Fas, Killer/DR5, and death-domain-containing protein PIDD (Lin et al.,
2000).

Figure 4. The p53 Pathway. Black ovals signify proteins involved in downstream
transcription by p53, the dark gray oval denote proteins involved in p53 regulation
and the light gray oval indicate proteins involved in p53 stabilization.
Regulation
Due to the fact that p53 can potentially cause so much harm to normal cell
cycle progression, it must be under tight regulation. Amongst the multiple negative
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regulators of p53, Mdm2 is considered key in protecting the cell from apoptosis.
Mdm2 functions as an E3 ubiquitin-ligase that is responsible for the ubiquitination of
both p53 and itself (Honda & Yasuda, 1999). Mdm2’s C-terminus RING finger
domain binds to p53’s N-terminus to allow ubiquitination and nuclear export of the
complex (Kubbutat et al., 1999). Once in the cytoplasm, the poly-ubiquitination acts
as a signal for proteasome-dependent degradation (Hicke & Dunn, 2003). Mdm2
becomes upregulated when p53 becomes activated because Mdm2 is a transcriptional
target of p53 putting these two cellular regulators in an autoregulatory loop (Oren et
al., 2002).
Stabilization
On the other hand there are also proteins that can stabilize p53 in the cell.
One of the most important ways for p53 to be stabilized is through acetylation by
p300 (Yuan et al., 1999). p53 requires the acetylation of p300 in order to induce cell
cycle arrest after irradiation. It is this binding that is responsible for arrest during G1,
yet it does not interfere with the p53-Mdm2 complex. However, DNA-damageinduced kinase Chk1 and Chk2 do interfere with this complex by phosphorylating the
N-terminus of p53, preventing the binding of Mdm2 and stabilizing p53 (Chehab et
al., 2000, Shieh et al., 2000).
B1R
Since the declaration of smallpox being eradicated from the world, vaccinia
virus has been the model for studying poxviruses, and its genome was the first
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orthopox virus to be completely sequenced (Goebel et al., 1990). Many of the genes
have since been characterized based on sequence homology as well as functional
testing. The B1 gene, for example, has been thoroughly examined in respect with its
homology to protein kinases. Since the discovery of B1R protein, others have
explored homologs in mammalian models, specifically human and mouse (LopezBorges & Lazo, 2000). These homologs have since been dubbed vaccinia-related
kinases (VRKs), with B1R being the prototypical model.
Protein Kinase
B1 is a 34-kDa essential gene for viral replication (Traktman et al., 1989). B1
is highly conserved in every member of the Poxvirus family except Molluscum
contagiosum virus (MCV), which may be why MCV exhibits such host restriction
(Boyle & Traktman, 2004). Upon sequencing B1, it was observed that B1 shows
significant homology to many protein kinases, due to its predicted ATP binding
domain, catalytic residues, phosphorylation receptor site, and its Gly-X-Gly-X-X-Gly
motif (Traktman et al., 1989). This glycine-rich motif is a consensus sequence found
in many nucleotide binding proteins, and its three-dimensional structure shows this as
an ATP binding site in protein kinases (Hanks et al., 1988). The presence of an
invariant lysine residue at position 149 offered evidence that supported the prediction
that B1R was a serine/threonine kinase.
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Activity Characteristics
B1 has been demonstrated as being expressed early in infection with temporal
changes in phosphorylation as infection progresses (Traktman et al., 1989) and that it
is oriented to the right (Rempel et al., 1990). It is this early expression that is required
for viral DNA replication (Traktman et al., 1989). However, B1R has demonstrated a
role not just in initiation of replication, but throughout the replication process with
many possible substrates (Rempel & Traktman, 1992b). The activity of B1R has been
further characterized in terms of optimal activity parameters. The optimal donor for
phosphorylation is ATP, while GTP shows much less activity. On the other hand,
VRK1 uses both ATP and GTP as phosphate donors, which makes it unique from
other casein kinases (Barcia et al., 2002). This activity of VRK1 also depends on
divalent cations, particularly Mn2+, Mg 2+ and Zn2+ to become active, as well as an
intact C-terminus for correct folding. The optimal pH for B1R’s kinase function is
between 8 and 9 (Lin et al., 1992). B1R has been confirmed to only phosphorylate
serine and threonine residues, with a preference to threonine. Within virion cores
there are many protein kinases present, of which B1R makes up about 4%, which is
approximately forty times the amount that is found within the virion envelope.
Targets
In addition to early expression, B1R can be found stably during late stage, as
well as located in virions (Banham & Smith, 1992). Due to this fact, B1R can interact
with a variety of targets (Table 1). In infected cells B1R protein localizes to
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cytoplasmic factories where virus DNA synthesis occurs. In order for viral DNA
synthesis to take place in the cell, there must be a switch from host DNA synthesis to
viral. The 40S ribosomal proteins S13, Sa and S2 have demonstrated phosphorylation
by other viral proteins that allows for a switch to viral mRNA translation with
temporal association and B1R has been shown to phosphorylate both Sa and S2
(Banham et al., 1993). This is possibly the reason for B1R’s presence in the virion.
B1R protein has also been shown to phosphorylate a single stranded DNA-binding
protein expressed by vaccinia virus (Beaud et al., 1995). This protein is the product
of the H5R gene that is phosphorylated at several threonine sites and thought to be
involved in virus assembly by targeting membranes and DNA-protein foci of viral
replication. It is this interaction of these two viral molecules that is able to inhibit the
host immune system by inhibiting CD1d1 T lymphocytes, by which the virus can
survive (Webb et al., 2006). To aid in the protection of vaccinia virus from the host
immune system and allow replication, B1R also targets α-2-macroglobulin, which
inhibits proteases within the coagulation cascade (Rempel & Traktman, 1992b).
MAPK
In viral infections, the MAPK pathway is often activated as a way of
guaranteeing the life cycle of the cell to allow the virus to replicate (Santos et al.,
2006a). In MAPK pathways several kinases are working together to activate
transcription factors and other kinases (Davis, 2000). In some circumstances these
kinases come together in a complex that is held together by the JIP scaffold (Jaeschke

23
et al., 2004). This complex can then go on to activate the c-Jun transcription factor
that is a component of the AP-1 complex (Weston & Davis, 2007). In vaccinia viral
infections, B1R has been shown to phosphorylate c-Jun and complex with the JIP
scaffold (Santos et al., 2006a). This interaction with the JIP scaffold leads to an
increase in the amount of MAPK bound to JIP1 and an increase in phosphorylation of
JNK. More stable interactions result in an increase in activation of transcription
factors such as c-Jun. With these methods B1R is capable of stabilizing c-Jun in two
different ways.
However, VRK2 interacts with the MAPK pathway in the opposite manner.
Both forms of VRK2 have been seen to block the stimulation of TAK1 signaling in
response to hypoxic conditions without the use of their kinase domains (Table 2)
(Blanco et al., 2007). TAK1 is a mitogen activated protein kinase kinase kinase
(MAPKKK) that is the first molecule to bind to the JIP1 scaffold to induce a response
to cellular stress. It has been shown that VRK2A is capable of forming a stable
complex with TAK1 the best, which can in turn determine the magnitude of the stress
response. VRK2 has also been shown to downregulate the activation of transcription
induced by the IL-1β signal by interfering with the response signal at the MAPK level
(Blanco et al., 2008). VRK2 is able to bind to the JIP1 signalsome, which
destabilizes the complex and displaces JNK.
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Table 1. Substrates Phosphorylated by Protein Kinases.
Kinases

Substrates

References

B1R

40S Ribosomal Protein S2

(Banham et. al., 1993)

40S Ribosomal Protein Sa

(Banham et. al., 1993)

α-2-macroglobulin

(Rempel & Traktman, 1992)

BAF

(Nichols et. al., 2006)

c-Jun

(Santos et. al., 2006a)

p53

(Santos et. al., 2004)

Vaccinia Virus H5R

(Beaud et. al., 1995)

ATF2

(Sevilla et. al., 2004)

BAF

(Nichols et. al., 2006)

Core Histones H2B, H3, H4

(Kang et. al., 2007)

p53

(Vega et. al., 2004)

BAF

(Nichols et. al., 2006)

p53 (B form only)

(Blanco et. al., 2006)

VRK1

VRK2

Table 2. Other Interactions With VRKs.
Proteins

Substrates

References

B1R

JIP1

(Santos et al., 2006a)

VRK1

CDK2

(Santos et al., 2006b)

SURVIVIN

(Santos et al., 2006b)

BHRF-1

(Li et. al., 2006)

JIP1

(Blanco et. al., 2008)

TAK1

(Blanco et. al., 2007)

VHR

(Kang & Kim, 2008)

VRK2

VRK3
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BAF
B1R, VRK1 and VRK2 are all capable of phosphorylating barrier-toautointegration factor (BAF) (Table 1) (Nichols et al., 2006). BAF is an essential,
conserved, 10-kDa protein that binds to LEM domains, anchors chromatin to nuclear
periphery, and inhibits the formation of the nuclear envelope (Segura-Totten et al.,
2002). When BAF becomes phosphorylated on Ser4 and to a lesser extent Thr2 and
Thr3, there is a decrease in interaction with the LEM domain, and a disruption of the
ability to bind to DNA (Nichols et al., 2006). This is most likely due to the relocation
from the normal nuclear location of the phosphorylated form to throughout the cell.
The hypothesis is that BAF becomes phosphorylated during prophase allowing
chromatin to condense, and then is later dephosphorylated during anaphase allowing
localization at the chromosomes and the recruitment of LEM proteins. BAF has been
shown to be required from the onset of anaphase until the nuclear envelope reforms in
telophase, where it is needed for assembly, but not maintenance (Gorjánácz et al.,
2007). During mitosis VRK remains associated with chromatin, continually
phosphorylating BAF to allow mitosis to occur correctly and without VRK1 the
nuclear envelope cannot form properly.
B1R’s phosphorylation is a mechanism for the virus to overcome the host’s
defense against viral replication (Wiebe & Traktman, 2007). Normally upon
infection, BAF relocates to areas of viral replication, binds to DNA, and inhibits DNA
synthesis. However, the virus counteracts this through the expression of B1R protein
that can phosphorylate BAF, which causes BAF to remain diffuse in the cell, unable
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to bind DNA. It is able to recognize viral DNA not through the sequence, but due to
its inappropriate location (Rahman & McFadden, 2007).
p53
However, B1R is not only found in the cytoplasm, but also in the nucleus of
the cell (Santos et al., 2004). Here B1R is able to hyperphosphorylate p53, the tumor
suppressor that is then downregulated in an Mdm2-dependent mechanism. B1R
phosphorylates p53 in the same location that Mdm2 interacts with, and in fact B1R
needs Mdm2 to be present in order to have effect. This is because when Mdm2 is not
present, B1R phosphorylation causes an accumulation of p53. By the downregulation
of p53, B1R inhibits apoptosis, allowing viral DNA synthesis to occur.
VRK1 and VRK2 also both target tumor suppressor p53 through
phosphorylation of Thr-18 which stabilizes and accumulates p53, and are thought to
normally help maintain a steady state of readiness (Vega et al., 2003). VRK1 does this
by phosphorylating p53 on the Thr18 residue, which stabilizes p53 by interfering with
the degradation of p53 by the proteasome, as well as recruiting other stabilizing
proteins p300 and Mdm4 (Vega et al., 2004). VRK2B can phosphorylate p53 to
induce accumulation and activate its transcriptional activity as well (Table 2), in a
mechanism very similar to the nature of VRK1 despite the differences in the last
ninety amino acids of these kinases (Blanco et al., 2006). It has been hypothesized
that this redundant function of VRK2B may be utilized when VRK1 is cytosolic.
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VRK1 Rescues B1R
VRK1 has even been shown to rescue a B1R mutant in regards to viral DNA
synthesis, without the phosphorylation of H5R protein (Boyle & Traktman, 2004).
hVRK1 is able to fully restore intermediate and late expression genes, while mVRK1
can only restore some genes. However, in both cases viral production is only partially
restored, which may be due to the fact that cellular VRK localizes to the nucleus
while vaccinia virus replicates in the cytoplasm.
142R
142R is a putative early serine/threonine kinase of tanapox virus (Nazarian et
al., 2007a). It has been found to exhibit homology with vaccinia viral protein B1R in
both sequence and genome location. This has thus led to the speculation that both
proteins will have similar transcriptional timing and function in the host cell. The
predicted kinase function is based on the residues found in 142R that are highly
conserved in most protein kinases.
Protein Kinases
Protein kinases make up a large family of enzymes that are responsible for
cellular responses to internal and external stimuli (Hanks et al., 1988). These
enzymes have a well conserved catalytic domain that most often lies near the Cterminus and is 250 to 300 amino acids in length. Within the catalytic domain there
are eleven major conserved subdomains (Table 3), which are separated by regions of
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lower conservation in the form of gaps or inserts. This alternating arrangement is a
common feature of homologous globular proteins (Chothia & Lesk, 1986), where the
conserved regions are active and the nonconserved make up the loops that bring the
active sites together (Hanks et al., 1988).
Table 3. Conserved Regions of Serine/threonine Kinases With Respect to Adenosine
3’, 5’-Monophosphate (cAMP)-dependent Protein Kinase Catalytic Subunit, α Form
(cAPK).
Subdomain

Motif

Function

Found in
142R

I

Gly-X-Gly-X-Gly

II

Lys72

Nucleotide Binding
Phosphotransfer and Proton
Transfer

III

Glu91

ATP Binding

VI

Val157

ATP Binding

Asp-Leu-Lys-Pro-GluAsn

ATP Binding

Yes

VII

Asp184, Phe185, Gly186

ATP Binding

Yes

VIII

Ala-Pro-Glu

Catalytic Domain Indicator

Yes

IX

Asp220,

ATP Binding

Yes

XI

Arg280

Gly225

Yes
Yes

ATP Binding

Serine/threonine Kinases
There are three major types of kinases: those that phosphorylate
serine/threonine, those that phosphorylate tyrosine and those that phosphorylate all
three amino acids (Hanks et al., 1988). Serine/threonine kinases then go on to be
further categorized based on the mode of regulation, whether they are retroviral
transforming proteins, their oncogenic potential, relatedness to yeast cell cycle control
relatives, or from herpes.
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Conserved Domains
Based on the prototypical protein kinase, bovine adenosine 3’, 5’monophosphate (cAMP)-dependent protein kinase catalytic subunit, α form (cAPK)
sequence there are nine identical amino acid residues: Gly52, Lys72, Glu91, Asp166,
Asn171, Asp184, Gly186, Glu208, and Arg280 (Hanks et al., 1988). There are also five
slightly less conserved amino acid residues present as Gly50, Val157, Phe185, Asp220,
and Gly225. Many of these conserved residues are responsible for binding with ATP
for phosphotransfer.
Within subdomain I there is a conserved consensus sequence of Gly-X-Gly-XX-Gly very near the N-terminus of the catalytic domain. This sequence is responsible
for binding nucleotides with the first Gly contacting the ribose and the second near
the terminal pyrophosphate (Sternberg & Taylor, 1984). Working with this sequence
are two hydrophobic residues lying upstream in positions one and seven, in addition
to an invariant valine two positions downstream, that may position these glycines
(Hanks et al., 1988). In subdomain II there is an invariant lysine at position 72 that is
directly involved in the phosphotransfer reaction and possibly proton transfer as well
(Kamps & Sefton, 1986). In 142R this lysine is located at residue 57.
The central core region, which includes subdomains VI through IX, is usually
the most highly conserved (Hanks et al., 1988). The invariant residues of subdomains
VI and VII have been implicated in the binding of ATP. Subdomain VIII contains a
key protein kinase catalytic domain indicator of the consensus triplet Ala-Pro-Glu
which is required for activity (Bryant & Parsons, 1983). However, in both B1R and

30
142R, this consensus triplet has been changed to Thr-Leu/Ile-Glu. This alteration is
still considered to be conserved because the two changes are to other non-polar
residues. This sequence has been shown to lie very near the catalytic site of the
enzyme (Hanks et al., 1988). Both subdomains VI and VIII contain consensus
sequences that are indicative of serine/threonine kinase activity (Hanks, 1987).
Implicated in ATP binding is the Asp-Leu-Lys-Pro-Glu-Asn consensus sequence of
subdomain VI (Hanks et al., 1988). While B1R and 142R do contain most of this
sequence, both have alterations for the Pro-Glu residues which have been changed to
Ala-Ser. Both changes retain polarity properties, however the Glu to Ser substitution
changes from an uncharged polar molecule to an acidic polar molecule. Once again
these changes are not considered to alter the conserved region’s function. Subdomain
VIII contains a sequence immediately on the N-terminus side of the Ala-Pro-Glu
sequence of Gly-Thr/Ser-X-X-Tyr/Phe-X-Ala-Pro-Glu.
Phylogeny
Upon phylogenetic analysis of known kinase catalytic domains, it was
determined that the evolution of these domains stem from gene duplication events
and/or speciation events (Hanks et al., 1988). Kinases that were found clustered were
at least 35% similar within the cluster, and they were found 20-25% similar when not
from the same cluster, although tyrosine kinases show higher clustering ability. We
propose to add 142R to this family and determine the relatedness to the plethora of
known kinases.
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MATERIALS AND METHODS
Cell Lines and Virus
All cell lines were obtained from American Type Culture Collection. Cos-7
were cultured in DMEM maintenance medium consisting of Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum
(Dot Scientific) and 1x antibiotic-antimycotic (Invitrogen). Owl Monkey Kidney
(OMK) cells were cultured in EMEM maintenance medium consisting of Eagle’s
minimum essential medium (EMEM) (Sigma) and supplemented with 10% newborn
calf serum (NBCS) (Life Technologies), 1.5 g/L sodium bicarbonate, 2 mM Lglutamine and antibiotics (penicillin G sodium 100 units/ml and streptomycin sulfate
100 µg/ml) (Invitrogen).
TPV-Kenya was obtained from the Center for Disease Control. Inoculated
cell monolayers were maintained in EMEM supplemented with 2% NBCS, 1.5 g/L
sodium bicarbonate, 2 mM L-glutamine and antibiotics.
Plasmid Constructs
pGEX-142R
TPV-Kenya DNA was isolated by phenol/chloroform extraction and ethanol
precipitation (Sambrook et al., 1989). The 142R ORF was then amplified by
polymerase chain reaction (PCR) using DyNAzyme polymerase (Fisher) and
oligonucleotides 5’- GGGGAATTCATGTCAAAAAACCAAG and 5’-
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CTCGAGTTAAAAATGGTT as primers. The product was then purified using the
QIAquick PCR purification kit (Qiagen), digested with EcoRI and XhoI
endonucleases and repurified by gel electrophoresis and the QIAquick gel extraction
kit (Qiagen). This fragment was inserted into the multiple cloning site (MCS) of the
pGEX-5X-1 vector (gift from Dr. PE Hoppe) to create pGEX-142R for expression in
bacteria.
pcDNA-142R
The pcDNA-142R plasmid was created in a similar fashion as the pGEX142R plasmid using oligonucleotides 5’- GGGCTCGAGATCTCAAAAAAC and 5’GGGGAATTCAAAATGGTTTAAAAATA as primers and pcDNA3.1myc/his
(Invitrogen).
p2KO∆142R
TPV-Kenya DNA was used to amplify a left flanking region, which spans
from the start of 141R and continues 210bp into 142R, using oligonucleotides 5’ GGGGGGGAGCTCAATTATGAACTACTGCTAT and 5’GGGGGGGCGGCCGCTTGATAAAATACTTGTTCTA as primers. A right
flanking region, which includes the last 230bp of 142R and the first 438bp of 143R
was amplified by PCR using oligonucleotides 5’GGGGGGGAATTCTAAAAGTGGATGAGTGGTAA and 5’CCCCCCCTCGAGTTTTCCTTTTTTGTGTATAG as primers. The PCR products
were then purified, digested with SacI and NotI endonucleases for the left flank and

33
EcoRI and XhoI endonucleases for the right flank, and gel purified. The two
fragments were then inserted into the p2KO plasmid (created by S. Conrad and D.
Jeng). This plasmid was created by inserting two pox viral promoters and a mCherry
tag into the MCS of pBluescript (Invitrogen). The resulting plasmid was designated
p2KO∆142R.
pcDNA-142R-GFP
The GFP region from the SV40 origin site to the SV40pA site of the
pTracer-CMV plasmid (Invitrogen) was amplified by PCR using oligonucleotides 5’GTTAACCCCAGGCTCCCCAGG and 5’- ATCGATGCAGTGAAAAAAATG as
primers. The PCR product was purified, digested with HpaI and ClaI endonucleases
and gel purified. This fragment was ligated into the pcDNA-142R plasmid after it
was digested with HpaI and ClaI endonucleases and gel purified to create the pcDNA142R-GFP plasmid.
pET21-142R and pPICZA-142R
The pcDNA-142R plasmid was digested with EcoRI and XhoI
endonucleases to isolate the fragment containing 142R. This fragment was then gel
purified and ligated into the MCS of pPICZ A vector to create pPICZA-142R plasmid
for expression in yeast and pET-21a(+) vector (gift from Dr. S Rossbach) to create
pET21-142R plasmid for expression in bacteria.
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pET15-142R
The pGEX-142R plasmid was digested with BamHI and XhoI
endonucleases to isolate the 142R fragment. This fragment was gel purified, ligated
to the linker oligonucleotide consisting of the two strands 5’- GATCCGGTACCCCA
and 5’- TATGGGGTACCG and inserted into the MCS of pET-15b vector (gift from
Dr. B Tripp) to create pET15-142R plasmid for expression in bacteria.
pET45-142R
The pGEX-142R plasmid was digested with EcoRI and XhoI endonucleases
to isolate the fragment containing 142R. This fragment was then gel purified and
ligated into the MCS of pET-45b(+) vector (Novagen), which was digested with the
HindIII endonuclease, blunted with DNA polymerase I and gel purified, to create
pET45-142R plasmid for expression in bacteria.
pET21-GA
142R was codon optimized for expression in E.coli using Geneart
(Invitrogen). The plasmid that was produced was digested with EcoRI and XhoI
endonucleases, gel purified and inserted into the MCS of pET-21a(+) vector to create
pET21-GA plasmid for expression in bacteria.
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shRNA Plasmids
Short hairpin RNA (shRNA) plasmids were created using the
pSUPERIOR.neo expression vector (OligoEngine). The BLOCK-iT RNAi program
(Invitrogen) was used to predict shRNA targeting 142R. The oligonucleotide 5’GATCCCCGCAGGTACGTACATAGCGATATAACGAATTATATCGCTATGTA
CGTACCTGCTTTTTGGAAA and 5’AGCTTTTCCAAAAAGCAGGTACGTACATAGCGATATAATTCGTTATATCG
CTATGTACGTACCTGCGGG were annealed and ligated into the pSUPERIOR.neo
vector according to manufacturer’s instruction to produce shRNA 464 plasmid, which
targets 142R starting at the 464 base pair from the beginning. Likewise
oligonucleotide 5’GATCCCCGCAGGAGCATATCCTTCTAGAAGACGAATCTTCTAGAAGGATA
TGCTCCTGCTTTTTGGAAA and 5’AGCTTTTCCAAAAAGCAGGAGCATATCCTTCTAGAAGATTCGTCTTCTAG
AAGGATATGCTCCTGCGGG were annealed and inserted into pSUPERIOR.neo
vector to create shRNA 652 plasmid. The control plasmids c-Jun and Fra were
created by Denise Smith as described (Smith & Bejcek, 2011).
Protein Expression and Purification
Bacterial Protein Expression
All plasmids for bacterial expression, including plasmids obtained from
Addgene p3113 GST-p53 (Huibregtse et al., 1991) and pGEX-4T MDM2 WT (Zhou
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et al., 2001), were expressed in Escherichia coli strains. Among those used were
BL21-A1 (gift from Dr. PE Hoppe), BL21-Star (gift from Dr. B Tripp), Rosetta (gift
from Dr. Huffman), Top10, DH5α and BL21-plysS. Transformed bacteria were
grown to an OD600 of 0.4 at 37oC, before the addition of 1 mM isopropyl-β-Dthiogalactopyranoside (IPTG) (US Biologicals) and 0.2% L-arabinose (for BL21-A1)
for induction of protein expression. Bacteria was then grown for 4 hours at either
21oC, 30oC or 37oC. Soluble protein was extracted by centrifugation and sonication.
It was then subjected to affinity chromatography on a glutathione-agarose column
(Novagen) for pGEX-142R, p3113 GST-p53 and pGEX-4T MDM2 WT. All other
bacterial produced protein were isolated using either a nickel or a TALONspin cobalt
column (Clontech) as all these proteins have His tags. Protein concentrations were
determined using a bicinchoninic acid (BCA) protein assay (Pierce) with a BSA
standard.
Cos-7 Cell Protein Expression
For expression in Cos-7 cells, the 142R protein was produced by
transfection of the pcDNA-142R plasmid with FuGENE 6 transfection reagent
(Roche), according to the manufacturer’s instruction. As determined by the
NanoDrop 2000 spectrophotometer, 10 µg of pcDNA-142R plasmid was transfected
into Cos-7 cells for 48 hours. Cells were then harvested in 1x cell lysis buffer
(Promega) with 1 mM phenylmethanesulfonylfluoride (PMSF), sonicated and
centrifuged. The whole cell lysate was then purified by TALONspin columns
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(Clontech). Elutions were pooled and concentrated by Centricon10 filter devices
(Millipore) at 4000rpm. Protein concentrations were determined with a BCA protein
assay (Pierce). Protein expressed from the pcDNA-142R-GFP and empty vector
pcDNA3.1 myc/his plasmids were treated in identical manner.
Yeast Protein Expression
For yeast expression pPICZA-142R was transformed into Pichia pastoris
GS115/pPICZ/lacZ Mut+ β-galactosidase from the Easy Select Pichia Expression Kit
(Invitrogen). Protein isolation was performed according to the manufacturer’s
recommendation.
Protein Kinase Assays
Protein kinase assays were performed in a solution containing 50 mM TrisHCl (pH 7.5), 10 mM MgCl2, 5 mM dithiothreitol, 100 µM vanadate, 10 µM [γ-32P]
ATP, and one of the following protein samples: 0.2 µg to 1 µg of 142R protein, 0.5 µg
142R-GFP protein or 0.6 µg pcDNA protein. Reactions were incubated at 30oC for 1
hour, before termination by the addition of sodium dodecyl sulfate (SDS) gel sample
buffer. Proteins were separated on 12% SDS-PAGE and exposed to Kodak X-Omat
LS film or a Molecular Dynamics storage phosphor screen overnight. Screens were
then imaged using the Storm860 scanner. Where indicated 85 µg dephosphorylated
α-casein (Sigma), 100 µg BSA (New England Biolabs), 7.6 µg MDM2 protein or 37.5
µg p53 protein were included in the reaction mixture.
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Recombinant Virus
To create the TPV∆142R virus, 80-90% confluent OMK cells were
inoculated with a 1X-lysate of TPV-Kenya for one hour. The media was then
replaced with DMEM maintenance media and placed at 37oC with 5% CO2 until the
pH returned to a normal level. Then the cells were transfected with either 2 µg
pcDNA-142R-GFP or p2KO∆142R plasmid (see Figure 5) with jetPRIME DNA
transfection reagent (Polyplus-transfection) according to manufacturer’s
recommendation. Media was replaced four hours post transfection. Four to seven
days later the cells were harvested, subjected to freeze/thawing on dry ice and
reinoculated in new plates with 25 µl, 50 µl, 100 µl or 200 µl. Individual red plaques
were picked from these plates, freeze/thawed, diluted 1:200 and reinoculated in new
plates. This process was repeated at least 3 times or until all plaques were
fluorescent. DNA was then harvested via phenol/chloroform extraction and subjected
to PCR to verify that 142R had been successfully removed from the virus.
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Figure 5. Plasmid Diagrams for Recombinant Virus Creation. The pcDNA-142RGFP plasmid contains a GFP gene inserted into the middle of 142R. The
p2KO∆142R plasmid contains a mCherry gene between the two ends of 142R, with
the middle of the gene removed. Both plasmids should integrate their fluorescence
genes into the TPV-Kenya genome at the 142R locus through recombination
generating knockout viruses.
shRNA
One microgram of pSUPERIOR.neo, pSUP-cJun, pSUP-Fra, shRNA 464
and shRNA 652 plasmids were all transfected into OMK cells in a 6-well plate with
jetPRIME DNA transfection reagent (Polyplus-transfection) according to
manufacturer’s recommendation. Media was replaced 4 hours post transfection.
Twenty-four hours post transfection, the cells were inoculated with TPV-GFP with an
MOI of 0.1 pfu/cell. One hour post inoculation the media was replaced with EMEM
maintenance media containing 0.4% methyl cellulose. In the sixth well there was no
plasmid transfection introduced. Four days later, cells were scraped, freeze/thawed on
dry ice, sonicated and diluted for viral quantitation.
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Viral Quantitation
To determine viral concentration, TPV-GFP was serially diluted from 10-2 to
10-5 and inoculated in 6-well plates with 400 µl per dilution (3 wells per dilution).
One hour post inoculation the media was replaced with EMEM maintenance media
containing 0.4% methyl cellulose. These plates were then incubated for 10 days at
37oC with 5% CO2. The media was then removed and cells were stained with 0.1%
crystal violet in 10% formaldehyde for 1 hour. Cells were then rinsed in deionized
water and air-dried. The average number of plaques were counted and used to
determine the total yield of virus.
Student’s t-Test
P values were calculated using Graphpad Prism software by unpaired
Student’s t-Test comparing each treatment to the control that contained no plasmid.
Differences with a P < 0.05 were considered as statistically significant.
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RESULTS
Protein Expression
pGEX Plasmids
In order to express protein for use in kinase assays, pGEX-5X-1 plasmid
(without an insert) was induced for protein expression in 2 different cell lines to
determine which cell line would express protein more efficiently. Samples were
separated on a 12% SDS-PAGE and stained with Coomassie blue (see Figure 6).
Since BL21-A1 cells appeared to express the most protein this cell line was utilized in
further expression experiments.
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Figure 6. Comparison of Cell Lines for Expression of the GST Protein From the
pGEX-5X-1 Plasmid. Lane M is the marker lane containing protein standards. Lane
2 shows that BL21-A1 has a higher level of protein expression upon the induction of
the plasmid, than that of lane 4 of DH5α.
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pGEX-142R, p3113 GST-p53 and pGEX-4T MDM2 WT plasmids were all
induced for expression of protein, which was then isolated using a glutathione column
or with a GST bead slurry and visualized on a 12% SDS-polyacrylamide gel stained
with Coomassie blue (see Figure 7). Protein from the pGEX-B1R plasmid was never
successfully isolated.
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Figure 7. Isolation of Protein Expressed From the pGEX-5X-1 and pGEX-142R
Plasmids. Lane M is the marker lane containing protein standards. Lanes 1-5 show
the protein induction of pGEX-5X-1 plasmid at varying culture volumes isolated with
a glutathione bead slurry. Lanes 7-11 show the protein induction of pGEX-142R
plasmid at varying bacterial volumes isolated with a GST bead slurry. While the
control plasmid yields more protein, both plasmids show a correlation of protein
levels with the culture volume.
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pET Plasmids
With the potential problems that a large GST tag may have on protein activity,
we attempted to express 142R as a fusion protein with the smaller 6x-His tag using
the pET series of vectors. Both 142R and B1R coding regions were cloned into pET45b(+) vector. Using BL21-A1 cells protein expression was attempted at 21oC, 30oC
and 37oC (see Figure 8). In addition protein from pGEX-142R plasmid was also
expressed in BL21-A1 cells at the same three temperatures. Protein expressed from
the pET-142R plasmid was purified by column chromatography using either nickel or
cobalt columns. pGEX-142R expressed protein was isolated using glutathione
columns. Although a band that was of the predicted molecular weight for the fusion
protein produced from the pET-142R plasmid could be visualized in whole cell
lysates, it failed to adhere to either column. For these samples whole cell lysate was
used in addition to the column isolates in case the protein was not abundant enough to
be seen with Coomassie staining.
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Figure 8. Protein Isolation Comparing Nickel and Cobalt Columns. Lane M is the
marker lane containing protein standards. Lanes 2-4 are elutions from a cobalt
column of protein expressed from the pET45-142R plasmid at a variety of
temperatures. Lanes 5-9 are five different fractions of protein expressed from the
pET45-142R plasmid from the elution off of a nickel column.
In order to produce a protein that can interact with cobalt columns, pET21142R plasmid was created. In this construct the His tag is on the C-terminus, whereas
the pET45-142R plasmid the His tag is on the N-terminus which can often inhibit the
ability of chimeras to interact with the column. pET21-142R and pET21-B1R
plasmids were both induced for protein expression in BL21-A1, BL21 Star, pLysS
and Rosetta2 cells. Lysates were subjected to cobalt column chromatography, the
eluted protein separated on a 12% SDS-PAGE and the gel stained with Coomassie
blue (see Figure 9). The lane that was loaded with the elution 2 fraction showed a
band of the expected molecular weight.
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Figure 9. Protein Expressed From the pET21-142R Plasmid Isolated Using Cobalt
Column Affinity Chromatography. Lane M is the marker lane containing protein
standards. Elution 2 fraction does show some protein at the correct molecular size.
To determine if protein levels could be increased by codon optimization, the
GeneArt program from Invitrogen was used to design an optimized version of 142R.
This DNA with appropriate restriction sites was purchased from Invitrogen and
cloned into the pET-21a(+) vector to create pET21-GA which was confirmed by
sequencing. Protein was expressed at 21oC, 30oC and 37oC, and along with protein
expressed from the pET-142R plasmid was isolated as previously described (see
Figure 10).
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Figure 10. Protein Expression From the pET21-142R and pET21-GA Plasmids. Lane
M is the marker lane containing protein standards. Lane 1 has protein isolated from
uninduced bacteria containing the pET21-142R plasmid. Lanes 2-4 has protein
expressed from the pET21-142R plasmid at 21oC, 30oC and 37oC. Lane 5 has protein
isolated from uninduced bacteria containing the pET21-GA plasmid. Lanes 6-8 has
protein expressed from the pET21-GA plasmid at 21oC, 30oC and 37oC. Lanes 3, 4
and 7 all show protein at the predicted molecular weight of 142R protein.
pPICZA Plasmids
To circumvent any potential problems such as misfolding in expressing
protein in a prokaryotic system, 142R was cloned into the yeast expression vector
pPICZ A (Invitrogen) to create pPICZA-142R. However, upon attempting to express
the protein using the Easy Select Pichia Expression Kit (Invitrogen), the yeast failed
to grow in repeated attempts. The few times yeast did grow, no 142R protein could
be detected from cell lysates (data not shown).
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pcDNA3.1myc/his Plasmids
Protein expression was also attempted in a mammalian system. Cos-7 cells
are derived from an African green monkey kidney cell line, CV-1, that have been
transformed with the SV40 virus. They express nuclear large T antigen as well as all
proteins necessary for replication of DNA that has an SV40 origin of replication
(Hancock, 1991). Any plasmid with the SV40 origin of replication in Cos-7 cells will
result in rapid plasmid replication to high copy number along with expression of
genes driven by an appropriate promoter. In this manner Cos-7 cells can quickly
express protein that undergoes normal posttranslational processing making them ideal
for transient expression of mammalian protein. The 142R ORF was cloned into the
pcDNA3.1myc/his vector for expression in Cos-7 cells creating pcDNA-142R. This
plasmid then had the GFP region of the pTracer-CMV plasmid cloned within the
142R region creating pcDNA-142R-GFP. Cos-7 cells were plated in 60mm dishes
and transfected with pcDNA-142R, pcDNA-142R-GFP or pcDNA3.1myc/his
plasmids.

Dishes were scraped, centrifuged, sonicated and subjected to cobalt

column chromatography. Protein expression was visualized by SDS-PAGE and
Coomassie blue staining (see below).
Kinase Assays
Bacterial Expressed Protein
Kinase assays yielded no kinase activity using protein derived from pGEX
plasmids (see Figure 11). Attempts were made at altering conditions, which included
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fixing and drying the gel for a range of time, varying the pH of the reaction, digestion
of GST away from 142R (see Figure 12) and exposing film for up to a week. There
was no activity that could be detected under any of these conditions.
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Figure 11. pGEX Plasmid Derived Protein Kinase Assay. Representative kinase
assay obtained using the GST fusion 142R protein. Lane M is the marker lane
containing protein standards. The first five lanes are proteins expressed from the
pGEX-142R plasmid with a variety of substrates. Lanes 6-9 are the proteins
expressed from pGEX-5X-1 plasmid with the same variety of substrates. The far
right lane is the positive control, which is a SNARK protein (kind gift of Dr. P.
Hoppe).
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Figure 12. Protein Produced with the pGEX Vector is Refractile to Digestion with
Factor Xa. Lane M is the marker lane containing protein standards. Lane 1 shows
protein expressed from the pGEX-142R plasmid. Lane 2 shows protein from lane 1
cleaved with Factor Xa. The arrow represents the predicted size of 142R without a
GST tag.

Since expression of 142R using the pGEX vector was not successful in
providing an active protein we next tried expressing 142R using the pET series of
vectors. We also tried expressing the pGEX plasmid at different temperatures.
Kinase assays were performed with proteins expressed with the pET45-142R (with a
His tag on the N-terminus) and pGEX-142R plasmids, but again no activity was
detected (data not shown). The type of casein (casein from bovine milk and αcasein), concentration of casein, pH, amount of 142R derived protein (1-10 µg),
concentration of ATP, temperature and time of incubation were all varied, but no
assays demonstrated activity.
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The next set of kinase assays used the protein fused to the His tag on the Cterminus of the pET-21 vector. A positive control casein kinase I was used to ensure
the assay was performing correctly, but no samples showed kinase activity (see Figure
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Figure 13. Protein Kinase Assay Using Protein Expressed From the pET-21 Plasmid.
This assay is a representation of results obtained with protein produced using the
pET-21 expression system. Lane M is the marker lane containing protein standards.
Lane 1 is the positive control, which is casein kinase I. Lanes 2-4 has protein
expressed from the pET21-142R plasmid from 21oC, 30oC and 37oC with substrate
p53. Lanes 5-7 has protein expressed from the pET21-GA plasmid from the same
three temperatures with substrate p53.
Cos-7 Cell Expressed Protein
Protein expressed in transfected Cos-7 cells from the pcDNA-142R, pcDNA142R-GFP or pcDNA3.1myc/his empty vector plasmids were visualized on
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Coomassie blue stained gels. These proteins were also used in protein kinase assays.
Proteins expressed from pcDNA-142R-GFP and pcDNA3.1myc/his are not easily
visualized on this gel due to a very low concentration of protein, as determined by the
Nanodrop. Whole cell lysates of any of these samples demonstrated phosphorylation
of p53 and was therefore used as a positive control. The 142R protein was able to
phosphorylate p53, but did not phosphorylate casein, BSA or MDM2. This indicated
that whatever role 142R plays in regulating p53 it is due to direct interaction with p53
and not due to effects on other p53 pathway components. The multiple bands
visualized in the lanes containing p53 correlate with the multiple bands that were in
the p53 preparation. Neither protein from the vector alone nor 142R protein disrupted
by GFP are able to phosphorylate p53.
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Figure 14. Protein Kinase Assay Using Protein Derived From the pcDNA Plasmids.
Panel A – Coomassie blue stained gel showing all protein samples used in the kinase
assay. Panel B – Protein kinase assay. Lane M is the marker lane containing protein
standards. Lanes 1-4 are the expressed proteins with p53. Lanes 5-7 are the pcDNA142R plasmid expressed protein with a variety of substrates. Lanes 8-11 are the
pcDNA-142R plasmid expressed protein in decreasing concentrations with p53.
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Creation of a Knockout Virus
pcDNA-142R-GFP Plasmid
The first plasmid that was used to try to create a 142R knockout virus was the
pcDNA-142R-GFP plasmid. The cloning of a GFP region within 142R allowed
enough TPV-142R sequence on either side of the GFP to allow for recombination
with the wild-type virus at the 142R locus and detection of recombinant plaques
exhibiting green fluorescence. However, after multiple transfection/infections no
fluorescent plaques were observed. Upon further investigation it was determined that
the CMV promoter would not be transcriptionally active and a different approach was
needed.
p2KO∆142R Plasmid
To change the promoter that was used to express the fluorescent protein the
p2KO∆142R plasmid was created. This plasmid has pox virus promoters driving
expression of mCherry. Around four days post transfection/infection red plaques
began to appear with many red plaques seen at seven days post infection (see Figure
15).
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Figure 15. Transfection/Infection of TPV-Kenya and p2KO∆142R. The panel on the
left shows infected OMK cells 4 days postinfection under visible light. The panel on
the right shows the same area under illumination at 580nm.
Viral plaques were isolated, diluted and reinoculated into new plates until
individual plaques could be isolated based on the expression of the mCherry proteins
red (see Figure 16).

Figure 16. Plaque Purification of TPV∆142R. The top pictures are at 40X and the
bottom pictures are at 100X magnification of the same plaque. The panels on the left
shows infected OMK cells 7 days postinfection under visible light. The panels on the
right shows the same area under illumination at 580 nm.
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Once recombinant virus appeared visually pure, based on the absence of nonfluorescent plaques, PCR was used to verify that the recombination took place at the
142R locus. Although plaques appeared pure, PCR demonstrated that isolates
contained detectable wild-type virus. This indicated that the mutant virus had not
been fully isolated from the wild-type virus which had been done in another knockout
virus lacking the 66R gene (Conrad and Essani, unpublished).
In a further attempt at purifying the mutant virus, three mutants were chosen
(all from separate transfection/infections), reinoculated at dilutions of 0.5 – 5 µl in 60
mm plates and new plaques picked at 3 days postinfection. This was done to try to
isolate plaques that were small to get good separation and no contamination from
wild-type plaques. These plaques were reinoculated at 5 µl in 60 mm plates for about
17 days. No wild-type TPV-Kenya plaques were visualized. Out of the 10 separate
viruses obtained only 4 replicated sufficiently for DNA to be obtained. This DNA
was used for PCR using 4 different primer sets (see Figure 17). The two wild-type
primer sets only show bands if wild-type TPV-Kenya is present as the forward primer
is located in the region of 142R that is removed in the knockout virus. The two
mutant primer sets only show a band if TPV∆142R is present as the forward primer is
located in the mCherry region. All four of these viruses contained both wild-type
DNA and mutant DNA (see Figure 17). This indicates that while the mutant virus is
present, it has not been successfully separated from the wild-type virus.

56
A
141R

Wild-type I
Wild-type II

mCherry
Mutant II

141R

Mutant I
Mutant II

B

w-t II
w-t I

2000

1000
800
600

1000
800
600

TPV∆142R - 1
TPV∆142R - 2
TPV∆142R - 3
TPV∆142R - 4
H2O

TPV∆142R - 4
H2O
TPV-Kenya

TPV∆142R - 3

TPV∆142R - 2

bp

2000
1500

400

Mutant II

Mutant I

TPV-Kenya
TPV∆142R - 1

TPV∆142R - 4
H2O

Wild-type II

TPV∆142R - 3
TPV∆142R - 4
H2O
TPV-Kenya
TPV∆142R - 1
TPV∆142R - 2
TPV∆142R - 3

bp

TPV-Kenya
TPV∆142R - 1
TPV∆142R - 2

Wild-type I

1500

400

m II
mI

200
200

Figure 17. PCR of Potential TPV∆142R. Panel A – Size and Location of PCR
Products. Panel B - The gel on the left are the results using the 2 wild-type primer
sets. The gel on the right are the results using the 2 mutant primer sets. A forward
primer is shared by wild-type I and II PCR reactions. Another forward primer is
shared by mutant I and II PCR reactions. A reverse primer is shared by wild-type I
and mutant I PCR reactions. Another reverse primer is shared by wild-type II and
mutant II PCR reactions.

One mutant virus was selected and rediluted 1:1000 in order to obtain well isolated
plaques. Individual plaques were picked and used for PCR (see Fig. 18). The wildtype virus primers should only amplify a product if wild-type TPV-Kenya is present
as the forward primer is located in the region of 142R that is removed in the knockout
virus. The mutant virus primers should only amplify a product if TPV∆142R is

57
present as the forward primer is located in the mCherry region. The ampicillin
resistance primers are for the ampicillin resistance gene which could be present in a
single cross-over event. All the plaques appear to be coinfected with TPV-Kenya and
TPV∆142R with no single cross-over event. This indicates that the presence of the
142R protein is required for viral replication.
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Figure 18. Individual Plaque PCR. Panel A - The pictures are at 40X magnification
with the panels on the left showing infected OMK cells 7 days postinfection under
visible light. The panels on the right shows the same area illuminated at 580 nm.
Panel B - The gel on the left uses the wild-type virus primers. The gel in the middle
uses mutant virus primers. The gel on the right uses primers that are for the
ampicillin resistance gene.
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142R is Necessary for Viral Replication
To determine if 142R was necessary for viral replication shRNAs that were
designed to target 142R mRNA starting at 464 bp or 652 bp of the 142R gene were
cloned into the pSuperior.neo vector. The empty vector was used as a control, along
with two plasmids pSUP-c-Jun and pSUP-Fra that have FRA and cJUN scrambled
sequence (Smith and Bejcek, 2011). Cells were photographed 4 days post-inoculation
(see figure 19). The virus appeared evenly distributed throughout all of the dishes
containing control plasmids, but the samples transfected with shRNA 464 and 652
plasmids contained large areas without viral plaques. Virus was harvested and
quantitated (see figure 20). After performing Student’s t-Test on the viral titer CPE,
both shRNA 464 and 652 plasmids showed significant (P < 0.05) reduction with P
values of 0.0351 and 0.0231 respectively. The three control plasmids had varying
levels of decreased CPE, but it was not significant with P values of 0.0537 for
pSuperior.neo, 0.3475 for pSUP-c-Jun and 0.8793 for pSUP-Fra plasmids.
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Figure 19. TPV-GFP in the Presence of shRNA Targeting 142R. The pictures are at
40X magnification with the panels in the visible columns showing infected OMK
cells 4 days postinfection under visible light. The panels in the fluorescence columns
shows the same area under UV fluorescence illuminated at 510 nm. Panel A - Pictures
of the four controls that did not target 142R. Panel B - Pictures of the two shRNA
samples targeting 142R that have marked decrease in fluroescence with 1 µg
transfections.
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Figure 20. TPV-142R shRNA Treatment Reduces Virion Production in OMK Cells.
Unpaired Student’s t-Test was performed comparing populations to a control sample
that received no plasmid transfection. Both shRNA 464 and 652 were significantly
reduced (indicated by *), while empty vector and nonsense controls were not. The
standard deviation is indicated by the error bars.
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DISCUSSION
Protein Expression and Kinase Activity
Production of active kinase in bacteria failed even though multiple tags at both
the N and C termini were tried. It is not known why no active protein could be
produced but it was most likely due to misfolding. Although it is the method other
laboratories have used to produce the related protein, B1R, for kinase studies (Rempel
& Traktman, 1992b). To increase the chances of getting protein into the correct
conformation, three temperatures were used during the induction of protein
expression. Often proteins require a specific temperature in which they will fold
correctly so by producing protein under different conditions a direct comparison of
protein could be performed in the expression of protein. However, none of these
samples exhibited kinase activity and it was concluded that none of these alterations
to protein expression corrected the folding problem. Further evidence that there was
misfolding occurring is the inability to cleave the GST tag with Factor Xa.
Other E. coli strains were used in an attempt to perhaps overcome a codon
bias (Gustafsson et al., 2004, Hilterbrand et al., 2012), and an optimized version of
142R for expression in BL21-Star was created as well. It has been shown that by
optimizing codon usage in poxvirus genes it can improve the transient expression in
mammalian cells (Barrett et al., 2006). However, this did not produce kinase function
either.
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Changes post protein expression were also done to determine if the kinase
assay was the problem including altering pH, incubation time, cation, concentration of
all components with no change in results. A buffer exchange was undertaken to
remove the imidazole after elution from the cobalt column. Since the imidazole can
cause interference with the His tag, so it seemed possible that an effect could also be
seen in the kinase assays. When introducing imidazole into the previously
functioning positive control, kinase activity diminished (data not shown). Despite the
fact that imidazole interfered with kinase activity, removing it still did not repair the
kinase function with the 142R protein. At this point further exploration into
prokaryotic expression of the 142R protein seemed ineffectual, so eukaryotic
expression was examined in mammalian cell culture.
Cos-7 cells are an ideal way to express a large amount of protein in a short
amount of time in an eukaryotic system (Hancock, 1991). By utilizing the large T
antigen, protein is highly expressed from plasmids containing a SV40 promoter to the
extent that the protein will destroy the cells with the overexpression. The kinase
assay showed phosphorylation of p53 by both whole cell lysate and column purified
142R protein. The fact that there are several bands around the 53 kDa area is most
likely due to either protein degradation, the p53 sample was not completely pure,
and/or multiple phosphorylation states. The reaction with p53 is specific, as MDM2
does not show phosphorylation. If 142R phosphorylates p53 on multiple residues,
then this could account for several sizes of p53. This circumstance seems quite likely
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in light of fact that B1R is known to hyperphosphorylate p53 on several residues
(Santos et al., 2004).
The expression of the 142R protein from this system may have shown activity
while the other systems did not for a variety of reasons. One reason is that the protein
is normally expressed in a eukaryotic system so it is possible it could not fold
correctly in a prokaryotic system. Although this would be a departure from B1R that
was produced in bacteria and had activity (Rempel & Traktman, 1992b). Another
reason is that after each step a mixture of protease inhibitors was added to the protein.
This was done when isolating B1R protein from vaccinia virus due to its apparent
instability to enable further experimentation with the protein (Traktman, personal
communication). Added precautions were taken by performing the kinase assays
immediately after isolation of the protein to ensure freezing the sample would not
affect kinase activity.
Knockout Virus Creation
Prior to this study, it was unknown whether 142R was necessary for
replication of tanapox virus as B1R is for vaccinia virus (Traktman et al., 1989). If
this was indeed the case, then a knockout would not be able to replicate in the absence
of wild-type virus. The original experimental design was to create a cell line that
constitutively expressed 142R protein so that the lack of a virally encoded 142R could
be overcome by the presence of the protein in the cell. However, repeated attempts at
creating a cell line that expressed 142R in OMK, U373 MG and U87 MG proved
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unsuccessful. OMK cells would appear to simply stop growing. U373 MG and U87
MG cells would become G418 resistant, but 142R could not be visualized by western
blot.
Other strategies included utilizing the presence of human homologue VRK to
overcome a 142R deficiency. VRK is known to be upregulated in certain cell types,
including kidney cells (Vega et al., 2003). By using OMK cells it was possible that
the presence of VRK may overcome the lack of 142R, in a similar fashion to the
rescue effect it has on B1R (Boyle & Traktman, 2004). Several
transfection/infections were performed, all resulting in red colonies; however, after
several rounds of plaque purifications the mutant virus was still not pure as
determined by PCR. Despite the absence of wild-type plaques by microscopy, PCR
repeatedly showed that both wild-type and mutant viruses were both present. This
implies that no pure mutant virus could be isolated or produced. The fact that a virus
lacking 142R has not been able to be isolated without the presence of the wild-type
virus indicates that 142R is a necessary gene that can be rescued with the presence of
the protein. Throughout the purification steps viral replication appeared to decrease
which suggests that as the amount of wild-type decreases so does the ability of the
mutant to replicate.
To further support this assertion, shRNA were designed to target 142R to
determine if knocking down the protein expression would also decrease viral
production. Both shRNA plasmid transfections resulted in a significant decrease in
virus production. Despite having a P value above the significant threshold, the empty
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vector control does appear to also have a decrease in virion production. While it is
unclear why this is occurring, the FRA and c-JUN plasmids do not show this effect.
These plasmids are arguably better controls in that they are actually expressing a
shRNA unlike the empty vector, thus being more indicative of how the shRNA is
acting upon the system.
Due to both shRNAs showing a decrease in virion production, while targeting
separate regions of the gene, it strongly suggests that by disrupting the 142R protein
expression the virus production decreases as well. Together with the data from the
attempted knockout virus creation, it is highly indicative of 142R being an essential
gene for tanapox viral replication.
Future Directions
With this knowledge, it is unlikely that a pure virus lacking 142R can be
obtained without a plasmid that can constitutively express 142R protein and possibly
using different cell line that is easily transfected but does not have issues growing
when sparsely seeded. Even if this virus was obtained the ability to use it as an
oncolytic virus to target p53- cells may have other constraints to overcome. While the
protein does show phosphorylation of p53, there are other functions of 142R that are
essential for virus replication and therefore use as an oncolytic therapy will be
problematic. B1R also has several other viral and cellular interactions (Banham et al.,
1993, Beaud et al., 1995, Santos et al., 2006a, Webb et al., 2006) and 142R should be
further characterized as to its role in the replication cycle of tanapox virus.
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To create a 142R knockout virus a plasmid that expresses the protein in a
stable cell line will need to be created and used to establish a 142R expressing cell
line that is capable of viral production.
If a cell line that constitutively expresses 142R protein cannot be created it
may be necessary to try to create a temperature sensitive mutant as was done for
studying B1R (Rempel & Traktman, 1992a). In regards to vaccinia virus, this was the
only way to study the gene because making a knockout was impossible due to it being
necessary for replication (Traktman, personal communication). This would allow
exploration of the interaction of 142R protein with proteins and genes to determine if
they are the same as B1R. To determine if VRK1 would restore replication of
tanapox virus a cell line with an increased concentration of VRK1 would need to be
created as well. If VRK1 cannot rescue the replication deficiency, then a knockout or
temperature sensitive mutant may be a possible oncolytic virus to target tumors that
have an upregulation of VRK1 and with a mutation in p53. Due to the fact that
VRK1 and p53 are in an autoregulatory loop, this happens regularly. In human lung
carcinomas, when p53 is mutated, it is unable to downregulate VRK1 (Valbuena et
al., 2007). In this situation a knockout of 142R that was rescued by VRK1 would
only be able to replicate in the tumor.
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